

LITERATURA

1. www.czso.cz
2. Zhang Y et al. Associations of Blood Pressure and Cholesterol levels During Young Adulthood With Later Cardiovascular Events, *J Am Coll Cardiol* 2019 July 23; 74(3): 330–341.
3. Ference et al. Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease, *JAMA*, 2/2019, E 1–11.
4. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk, *European Heart Journal* (2019) 00, 1–78.
5. SCORE2 working group and ESC Cardiovascular risk collaboration: SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe *European Heart Journal*, Volume 42, Issue 25, 1 July 2021, Pages 2439–2454.
6. SCORE2-OP working group and ESC Cardiovascular risk collaboration: SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. *European Heart Journal*, Volume 42, Issue 25, 1 July 2021, Pages 2455–2467.
7. Sabatine MS, Giugliano RP, Keech AC, for the FOURIER Steering Committee and Investigators: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease, *N Engl J Med* 2017; 376:1713–1722.
8. Feron O, Dessy C, Desager JP et al. Hydroxy-methylglutaryl-coenzyme A inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveoline abundance. *Circulation* 2001; 103: 113–118.
9. Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (The CURVES Study). *Am J Cardiol* 1998; 81: 582–587.
10. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet*. 2003 Apr 5; 361(9364): 1149–1158.
11. Gupta A, Mackay J, Whitehouse A et al. ASCOT Legacy study. *Lancet* 2018; 392: 1127–1137.
12. Widimský J Jr, Filipovský J, Ceral F et al. Doporučení pro diagnostiku a léčbu arteriální hypertenze ČSH 2017, Hypertenze a kardiovaskulární prevence, Supplementum, 2017.
13. Zlatohlávek L et al. Klinická dietologie a výživa, CurrentMedia, Praha, 2016.
14. McAreavey D, Robertson JIS. Angiotensin converting enzyme inhibitors and moderate hypertension. *Drugs* 1990; 40: 326–345.
15. Fox KM. The EUROpean Trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet* 2003; 362: 782–788.
16. Bruining N, deWinter S, Roelandt JR et al. The Perspective study, *Coron Artery Dis* 2009, 20: 409–414.
17. Špinar J, Vítovec J. Studie ADVANCE. *Remedia* 2008; 18: 168–170.
18. van Vark LC, Bertrand M, Akkerhuis KM et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. *Eur Heart J* 2012; 33: 2088–2097.
19. Bruno et al. Early and Supernormal Vascular Aging, *Hypertension*, 2020; 76: 1–9.

SLEDUJTE NÁS NA FACEBOOKU

AKTUÁLNÍ INFORMACE
ze vzdělávání lékařů a lékárníků

- 📘 odemykáme články k aktuálním tématům
- 📢 upozorňujeme na blížící se vzdělávací akce
- 📖 informujeme o nových on-line kurzech s registrací zdarma
- 🏆 připravujeme soutěže o vstupenky na kongresy a předplatné časopisů ...

<https://www.facebook.com/SolenMedicalEducation/>

